Multi-institutional phase II, randomized dose finding study of defibrotide (DF) in patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Promising response rate without significant toxicity in a high risk population.
Journal articles
- Journal
Richardson, PG; Warren, DL; Momtaz, P; Soiffer, R; Antin, JH; Spitzer, T; Avigan, D; Wei, LJ; Jin, Z; Rifai, N; Bradwin, G; Vredenburgh, J ...
Published in: BLOOD
November 16, 2001
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2001
Volume
98
Issue
11
Start / End Page
853A / 853A
Publisher
AMER SOC HEMATOLOGY
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
Citation
APA
Chicago
ICMJE
MLA
NLM
Richardson, P. G., Warren, D. L., Momtaz, P., Soiffer, R., Antin, J. H., Spitzer, T., … Guinan, E. C. (2001). Multi-institutional phase II, randomized dose finding study of defibrotide (DF) in patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Promising response rate without significant toxicity in a high risk population. BLOOD, 98(11), 853A-853A.
Richardson, P. G., D. L. Warren, P. Momtaz, R. Soiffer, J. H. Antin, T. Spitzer, D. Avigan, et al. “Multi-institutional phase II, randomized dose finding study of defibrotide (DF) in patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Promising response rate without significant toxicity in a high risk population.” BLOOD 98, no. 11 (November 16, 2001): 853A-853A.
Richardson PG, Warren DL, Momtaz P, Soiffer R, Antin JH, Spitzer T, et al. Multi-institutional phase II, randomized dose finding study of defibrotide (DF) in patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Promising response rate without significant toxicity in a high risk population. BLOOD. 2001 Nov 16;98(11):853A-853A.
Richardson, P. G., et al. “Multi-institutional phase II, randomized dose finding study of defibrotide (DF) in patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Promising response rate without significant toxicity in a high risk population.” BLOOD, vol. 98, no. 11, AMER SOC HEMATOLOGY, Nov. 2001, pp. 853A-853A.
Richardson PG, Warren DL, Momtaz P, Soiffer R, Antin JH, Spitzer T, Avigan D, Wei LJ, Jin Z, Rifai N, Bradwin G, Vredenburgh J, Kurtzberg J, Martin PL, Vogelsang G, Arai S, Chen A, McDonald GB, Murray K, Iacobelli M, Guinan EC. Multi-institutional phase II, randomized dose finding study of defibrotide (DF) in patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Promising response rate without significant toxicity in a high risk population. BLOOD. AMER SOC HEMATOLOGY; 2001 Nov 16;98(11):853A-853A.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2001
Volume
98
Issue
11
Start / End Page
853A / 853A
Publisher
AMER SOC HEMATOLOGY
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology